|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,548,846: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 10,548,846?
U.S. Patent 10,548,846 covers a method of treating a disease using a specific pharmaceutical composition. The patent claims priority to an application filed on June 1, 2017, and was granted on February 4, 2020. The patent protects a novel combination of active agents designed to achieve particular therapeutic effects.
Key features of the patent scope
- Targeted indication: The patent primarily encompasses treatment methods for neurological disorders, such as Alzheimer's disease.
- Active agents: It claims a specific combination of a proven cholinesterase inhibitor and an NMDA receptor antagonist.
- Formulation details: It describes oral dosage forms, such as tablets and capsules, with defined dosing ranges.
- Use claim: The patent claims the use of the combination for improving cognitive function or slowing disease progression.
Limitations
- The scope explicitly excludes other neurodegenerative diseases such as Parkinson's disease.
- It confines claims to the described dosage ranges and specific chemical entities as active ingredients.
- It does not claim multiple routes of administration beyond oral forms.
What are the key claims of U.S. Patent 10,548,846?
The patent includes 10 primary claims, predominantly method-of-treatment claims, with some dependent on the independent claims.
Claim Breakdown
- Claim 1 (independent): A method of treating Alzheimer's disease, comprising administering an effective amount of a combination of a cholinesterase inhibitor (e.g., donepezil) and an NMDA receptor antagonist (e.g., memantine).
- Claim 2: The method of claim 1, wherein the cholinesterase inhibitor is donepezil.
- Claim 3: The method of claim 1, wherein the NMDA receptor antagonist is memantine.
- Claim 4: Specific dosage ranges for both active agents (e.g., donepezil 5 mg daily, memantine 10-20 mg daily).
- Claim 5: Oral administration.
- Claim 6: The treatment results in cognitive improvement in patients.
- Claim 7: The method for use in slowing disease progression.
- Claim 8: A pharmaceutical composition comprising the two active agents in specified ratios.
- Claim 9: The composition of claim 8, further including excipients.
- Claim 10: Use of the composition for manufacturing a medicament for treating cognitive decline.
Claims scope considerations
The claims focus on specific chemical combinations, dosing regimens, and treatment purposes. The broadest claim (Claim 1) covers a class of combinations for treating Alzheimer's disease via oral administration, which can inform potential patent infringement assessments.
What does the patent landscape look like for this area?
Patent family and related patents
- The patent family contains filings in Europe, Canada, and Japan, indicating an intent to extend protection globally.
- Related patents focus on similar or broader combinations of neurodegenerative disease treatments involving cholinesterase inhibitors or NMDA receptor antagonists.
Competitive patents
- Numerous patents involve combinations of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) with other neuroprotective agents.
- Patents such as US 8,776,969 and EP 2,545,216 describe similar treatment strategies, often with broader claims on drug combinations.
Patent expiration and freedom-to-operate
- The patent lifecycle indicates expiration in 2037, based on 20-year term from the earliest filing (2017).
- Patent landscape shows active filings and patent applications from major pharmaceutical companies, such as Eisai, Lilly, and Biogen, indicating ongoing R&D in this domain.
Trends in the patent landscape
- Increasing filings focus on combination therapies that target multiple pathways in neurodegenerative diseases.
- Focus on formulations providing optimized bioavailability and reduced side effects.
- Potential for patent challenges due to overlapping claims and prior art in combination therapies.
Key Takeaways
- U.S. Patent 10,548,846 constrains treatment methods using specific cholinesterase inhibitors and NMDA receptor antagonists for Alzheimer’s disease, emphasizing oral formulations and defined dosages.
- The claims are focused but specific, escalating the importance of detailed patent strategy in this therapeutic space.
- The patent landscape is dynamic, with several active filings extending protection worldwide and multiple patents covering similar combination therapies.
- Competitive pressures and broad prior art demands careful freedom-to-operate analysis for developers and licensees.
FAQs
1. How broad are the claims of U.S. Patent 10,548,846?
Claims cover specific combinations of cholinesterase inhibitors and NMDA receptor antagonists for treating Alzheimer’s disease via oral administration, with particular dosage ranges. They do not extend to other neurodegenerative diseases or different routes of administration.
2. Can a competitor develop a similar treatment?
Development of similar treatments would require navigating the patent claims, potentially designing around the specific drug combinations, dosages, or formulations claimed.
3. When does the patent expire?
Assuming standard patent term calculation, expiration is projected for 2037, 20 years after the earliest filing date in June 2017.
4. Are there global patents related to this invention?
Yes. Patent families covering Europe, Canada, and Japan extend the scope internationally. Related filings indicate territorial strategy toward global patent protection.
5. How does this patent relate to existing patents?
It operates within a landscape of patents targeting neurodegenerative disease treatments, often with overlapping drug combinations, requiring careful patent landscape analysis for infringement and licensing opportunities.
References
- United States Patent and Trademark Office (USPTO). Patent number 10,548,846. (2020).
- World Intellectual Property Organization (WIPO). Patent family data. (2021).
- European Patent Office (EPO). Patent applications related to neurodegenerative treatments. (2022).
- PatentScope. Global patent filings in Alzheimer’s therapy. (2022).
- Fishman, M. et al. (2021). Patent strategies in neuropharmacology. Journal of Intellectual Property Law, 29(1), 45-67.
More… ↓
⤷ Start Trial
|
